Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol
Primary Purpose
Otitis Media
Status
Unknown status
Phase
Phase 1
Locations
China
Study Type
Interventional
Intervention
0.1% Pazufloxacin Mesilate Ear Drops
0.3% Pazufloxacin Mesilate Ear Drops
0.5% Pazufloxacin Mesilate Ear Drops
Pazufloxacin mesilate injection
Sponsored by
About this trial
This is an interventional treatment trial for Otitis Media focused on measuring safety and bioavailability
Eligibility Criteria
Inclusion Criteria:
- Aged 18-65 years old, both gender;
- Patients with acute or chronic suppurative otitis media, need to be treated partially by antimicrobial agents;
- Written informed consent form.
Exclusion Criteria:
- Allergic to quinolones antibiotics or severe allergic constitution;
- Not able to collect otorrhea during the trial;
- High severity with the need of combined antibiotics treatment;
- Induced by pathogens, e.g.: fungus, virus (myringitis bullosa);
- Combined otitis externa (e.g.: ear cellulitis, mumps), intracranial or extracranial complication (meningitis, cerebral abscess, thrombophlebitis of sigmoid sinus, Bezold's abscess, ear subperiosteal abscess);
- Severe disease of cerebral, cardiopulmonary, renal hepatic, circulatory system;
- Life-threatening disease, e.g.: malignant tumor or AIDS.
- Renal hepatic dysfunction (ALT, AST ≥ 1.5 times of normal maximum level, Cr > normal maximum level);
- Confirmed or suspected of alcohol/drug abuse record;
- Neurological or psychiatric disease leading to inability of cooperation or not willing to follow the protocol or instruction;
- Feminine patients who are in gestational, lactation period or having a birth plan in short-term;
- Enrolled into other clinical trial in the past 3 months;
- Not suitable for this trial according to investigator's judgment;
Sites / Locations
- Qingdao Municipal HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Active Comparator
Arm Label
0.1% Pazufloxacin Mesilate Ear Drops
0.3% Pazufloxacin Mesilate Ear Drops
0.5% Pazufloxacin Mesilate Ear Drops
Pazufloxacin mesilate injection
Arm Description
10 drips for ear dropping, 10 minutes for ear bath
10 drips for ear dropping, 10 minutes for ear bath
10 drips for ear dropping, 10 minutes for ear bath
0.3g, 30 minutes for ventricular injection
Outcomes
Primary Outcome Measures
safety and tolerance of pazufloxacin mesilate ear drops
Any changes in vital signs; AE/SAE number
Secondary Outcome Measures
PK of pazufloxacin mesilate ear drops
blood samples will be collected at 0, 0.5, and one of the followed time points 2, 4, 6, 8 hours. AUC will be calculated based on the pazufloxacin mesilate concentration at above timepoints in blood.
PK of pazufloxacin mesilate ear drops
blood samples will be collected at 0, 0.5, and one of the followed time points 2, 4, 6, 8 hours. Cmax will be calculated based on the pazufloxacin mesilate concentration at above timepoints in blood.
Full Information
NCT ID
NCT02592096
First Posted
July 15, 2015
Last Updated
October 28, 2015
Sponsor
Lee's Pharmaceutical Limited
1. Study Identification
Unique Protocol Identification Number
NCT02592096
Brief Title
Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol
Official Title
A Single Dose Phase I Clinical Study of Pazufloxacin Mesilate Ear Drops for the Patients With Otitis Media
Study Type
Interventional
2. Study Status
Record Verification Date
October 2015
Overall Recruitment Status
Unknown status
Study Start Date
July 2015 (undefined)
Primary Completion Date
January 2016 (Anticipated)
Study Completion Date
February 2016 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Lee's Pharmaceutical Limited
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
To investigate the safety, tolerance, dynamic percolation model of single dose usage pazufloxacin mesilate ear drops for patients with acute suppurative otitis media or chronic suppurative otitis media
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Otitis Media
Keywords
safety and bioavailability
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
32 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
0.1% Pazufloxacin Mesilate Ear Drops
Arm Type
Experimental
Arm Description
10 drips for ear dropping, 10 minutes for ear bath
Arm Title
0.3% Pazufloxacin Mesilate Ear Drops
Arm Type
Experimental
Arm Description
10 drips for ear dropping, 10 minutes for ear bath
Arm Title
0.5% Pazufloxacin Mesilate Ear Drops
Arm Type
Experimental
Arm Description
10 drips for ear dropping, 10 minutes for ear bath
Arm Title
Pazufloxacin mesilate injection
Arm Type
Active Comparator
Arm Description
0.3g, 30 minutes for ventricular injection
Intervention Type
Drug
Intervention Name(s)
0.1% Pazufloxacin Mesilate Ear Drops
Intervention Type
Drug
Intervention Name(s)
0.3% Pazufloxacin Mesilate Ear Drops
Intervention Type
Drug
Intervention Name(s)
0.5% Pazufloxacin Mesilate Ear Drops
Intervention Type
Drug
Intervention Name(s)
Pazufloxacin mesilate injection
Primary Outcome Measure Information:
Title
safety and tolerance of pazufloxacin mesilate ear drops
Description
Any changes in vital signs; AE/SAE number
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
PK of pazufloxacin mesilate ear drops
Description
blood samples will be collected at 0, 0.5, and one of the followed time points 2, 4, 6, 8 hours. AUC will be calculated based on the pazufloxacin mesilate concentration at above timepoints in blood.
Time Frame
24 hours
Title
PK of pazufloxacin mesilate ear drops
Description
blood samples will be collected at 0, 0.5, and one of the followed time points 2, 4, 6, 8 hours. Cmax will be calculated based on the pazufloxacin mesilate concentration at above timepoints in blood.
Time Frame
24 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Aged 18-65 years old, both gender;
Patients with acute or chronic suppurative otitis media, need to be treated partially by antimicrobial agents;
Written informed consent form.
Exclusion Criteria:
Allergic to quinolones antibiotics or severe allergic constitution;
Not able to collect otorrhea during the trial;
High severity with the need of combined antibiotics treatment;
Induced by pathogens, e.g.: fungus, virus (myringitis bullosa);
Combined otitis externa (e.g.: ear cellulitis, mumps), intracranial or extracranial complication (meningitis, cerebral abscess, thrombophlebitis of sigmoid sinus, Bezold's abscess, ear subperiosteal abscess);
Severe disease of cerebral, cardiopulmonary, renal hepatic, circulatory system;
Life-threatening disease, e.g.: malignant tumor or AIDS.
Renal hepatic dysfunction (ALT, AST ≥ 1.5 times of normal maximum level, Cr > normal maximum level);
Confirmed or suspected of alcohol/drug abuse record;
Neurological or psychiatric disease leading to inability of cooperation or not willing to follow the protocol or instruction;
Feminine patients who are in gestational, lactation period or having a birth plan in short-term;
Enrolled into other clinical trial in the past 3 months;
Not suitable for this trial according to investigator's judgment;
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Weiguo Xue, MD
Phone
+86-532-82789159
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Weiguo Cue, MD
Organizational Affiliation
Qingdao Municipal Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Qingdao Municipal Hospital
City
Qingdao
ZIP/Postal Code
266011
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Weiguo XUE, MD
12. IPD Sharing Statement
Learn more about this trial
Pazufloxacin Mesilate Ear Drops Clinical Trial Protocol
We'll reach out to this number within 24 hrs